Is HCA or REGN cheaper?

On trailing earnings, HCA is cheaper: HCA trades at a 13.65 P/E and REGN at 14.98.

Which has grown faster, HCA or REGN?

Over the past five years, REGN grew revenue faster — HCA at a 7.73% CAGR versus REGN at 10.16%.

Does HCA or REGN pay a bigger dividend?

HCA yields 0.76% and REGN yields 0.59% based on trailing dividends and the latest price.

Is HCA or REGN more profitable?

REGN runs the higher net margin — HCA at 8.89% versus REGN at 29.65%.

Which has been the better investment, HCA or REGN?

Over the past 10-year, HCA delivered the higher annualized total return — HCA at 18.63% versus REGN at 5.29%. Past performance doesn't predict future results.

HCA Healthcare, Inc. (HCA) vs Regeneron Pharmaceuticals, Inc. (REGN)

HCA leads on 9 of 16 compared metrics.

A side-by-side comparison of HCA Healthcare, Inc. and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 16, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Regeneron Pharmaceuticals, Inc.

$62.78B

$614.98Healthcare

Total return — HCA vs REGN

growth of $100 · last 15y

HCA +1179.6%REGN +1448.8%REGN compounded faster

HCA REGN

HCA vs REGN: by the numbers

•HCA is the larger company ($88.05B vs $62.78B market cap).
•HCA trades at the lower earnings multiple (13.65 vs 14.98 P/E).
•REGN converts more revenue to profit (29.65% vs 8.89% net margin).
•REGN grew revenue faster over the past five years (10.16% vs 7.73% CAGR).
•HCA pays the higher dividend yield (0.76% vs 0.59%).

Which is better, HCA or REGN?

Metric tally: HCA 9 · REGN 7

It depends on what you're optimizing for:

ValueHCA(lower P/E)

GrowthREGN(faster 5Y revenue CAGR)

IncomeHCA(higher dividend yield)

QualityHCA(higher ROIC)

Metrics side by side

Valuation

Metric	HCA	REGN
P/E ratio	13.65●	14.98
Forward P/E	11.96	11.36●
P/S ratio	1.18●	4.44
P/B ratio	—	2.11
PEG ratio	0.56●	3.38
EV / EBITDA	8.86●	11.48
FCF yield	8.81%●	6.27%

Profitability

Metric	HCA	REGN
Gross margin	34.92%	84.55%●
Operating margin	15.67%	24.32%●
Net margin	8.89%	29.65%●
ROE	-112.56%	14.08%●
ROIC	18.53%●	8.51%

Dividends

Metric	HCA	REGN
Dividend yield	0.76%●	0.59%
Payout ratio	10.48%	8.45%

Growth (annualized)

Metric	HCA	REGN
Revenue CAGR (5Y)	7.73%	10.16%●
EPS CAGR (5Y)	20.90%●	5.70%
FCF CAGR (5Y)	1.92%	15.42%●
Total return CAGR (5Y)	14.89%●	3.22%

Frequently asked

Which is better, HCA or REGN?: It depends on your goal. value: HCA (lower P/E); growth: REGN (faster 5Y revenue CAGR); income: HCA (higher dividend yield); quality: HCA (higher ROIC). Across all compared metrics, HCA leads 9 to 7.
Is HCA or REGN cheaper?: On trailing earnings, HCA is cheaper: HCA trades at a 13.65 P/E and REGN at 14.98.
Which has grown faster, HCA or REGN?: Over the past five years, REGN grew revenue faster — HCA at a 7.73% CAGR versus REGN at 10.16%.
Does HCA or REGN pay a bigger dividend?: HCA yields 0.76% and REGN yields 0.59% based on trailing dividends and the latest price.
Is HCA or REGN more profitable?: REGN runs the higher net margin — HCA at 8.89% versus REGN at 29.65%.
Which has been the better investment, HCA or REGN?: Over the past 10-year, HCA delivered the higher annualized total return — HCA at 18.63% versus REGN at 5.29%. Past performance doesn't predict future results.

Go deeper

Full HCA analysis Full REGN analysis Interactive comparison tool

Dig into the metrics

HCA Healthcare P/E ratio Regeneron Pharmaceuticals P/E ratio HCA Healthcare dividend yield Regeneron Pharmaceuticals dividend yield HCA Healthcare ROE Regeneron Pharmaceuticals ROE HCA Healthcare operating margin Regeneron Pharmaceuticals operating margin HCA Healthcare revenue growth Regeneron Pharmaceuticals revenue growth HCA Healthcare free cash flow Regeneron Pharmaceuticals free cash flow

HCA Healthcare & Regeneron Pharmaceuticals appear in these rankings

Highest ROIC Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 16, 2026.